Adva Biotechnology Ltd. has developed an innovative Automated Autologous Cell Manufacturing Platform that leverages its proprietary Continuous Adaptive Multi-Parameter (CAMP) technology. This platform addresses the challenges associated with traditional autologous cell therapy manufacturing, which often suffers from labor-intensive processes and limited in-process controls. By utilizing advanced optical and biological sensors, the system continuously monitors and optimizes 14 critical parameters in real-time, ensuring high cell quality and performance. The platform facilitates a fully automated, end-to-end cell growth process within a single chamber, allowing for seamless transitions from cell activation and transduction to large-scale cell expansion.

The company’s technology supports various applications in cell therapy, including the production of Natural Killer (NK) cells, Chimeric Antigen Receptor T-cells (CAR-T), T-cell Receptor (TCR) therapies, and Tumor-Infiltrating Lymphocytes (TILs). Additionally, Adva Biotechnology is involved in the manufacturing of exosomes and viruses, which are increasingly important in the biopharmaceutical industry. The platform's design includes features such as a single-use closed system, remote access capabilities, and the ability to scale up or out, all aimed at enhancing the efficiency and effectiveness of advanced cell therapies in clinical settings.

Israel

Valuing Life, Granting Advanced Therapies to Patients- that Is Adva Biotechnologyâs Vision and goal.

Adva Biotechnology developed the ADVA-X3- a simple, smart, easy to use, automated, sensors-based, flexible cell manufacturing platform.

The ADVA-X3 enables full manufacturing process based on the CAMPâ¢ technology, of different applications, such as CAR-T, TCR, TIL, NK, Exosomes, Viruses and More.

Adva Biotechnology Ltd.

Company Details